Profitability Metrics

Gross Margin
51.05%
Operating Margin
10.68%
Net Margin
3.73%

Efficiency Metrics

Revenue per Expense Ratio
1.12
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
17.82%
Income Tax Rate
20.88%
EPS
1.2500000000

Balance Sheet Analysis

Current Ratio
0.77
Cash Ratio
0.22
Working Capital
$-460.70M
Debt to Equity
1.73
Debt to Assets
49.45%
Equity Ratio
28.60%

Cash Flow Analysis

Operating Cash Flow Ratio
14.95%
Free Cash Flow Ratio
5.18%
CapEx to Revenue
9.77%
Dividends Paid
$462.60M
Stock Buybacks
$16.90M
Total Shareholder Returns
$479.50M
Cash Position Change
10.51%

Key Takeaways (2024 FY)

  • Revenue declined by 19.242831541219%, indicating potential market challenges
  • Maintained positive net income growth despite revenue changes
  • Increased dividend payments by 0.66%

Detailed Growth Metrics

Core Performance

Revenue
-19.24%
Net Income
117.91%
EPS
117.46%
Operating Income
153.32%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
-1.20%
Operating Cash Flow
6.78%
Free Cash Flow
190.23%

Balance Sheet Health

Assets
-1.97%
Debt
-7.88%
Book Value per Share
-3.39%
Inventory
-5.08%

Shareholder Returns

Dividends per Share
0.66%
Shares Outstanding
2.57%

Long Term Trends

3Y Revenue/Share
-5.94%
5Y Revenue/Share
-18.34%
3Y Dividend/Share
9.55%
5Y Dividend/Share
32.15%